Literature DB >> 17312157

A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII.

Ali Jafarshad1, Morten H Dziegiel, Rasmus Lundquist, Leif K Nielsen, Subhash Singh, Pierre L Druilhe.   

Abstract

Clinical experiments have shown that the Ab-dependent cell-mediated inhibition of Plasmodium falciparum is a major mechanism controlling malaria parasitemia and thereby symptoms. In this study, we demonstrate that a single merozoite per monocyte (MN) is sufficient to trigger optimal antiparasitic activity. Using particulate Ag as pseudomerozoites, we show that only Ags, and no other parasite-derived factor, are required to trigger MN activation and that a single Ag is as potent as the complex combination of Ags constituting the merozoite surface. Moreover, we found that soluble Ags binding at least two Abs are as effective as the parasite at stimulating MN and that nonmalarial Ags are as efficient provided they are targeted by cytophilic Abs. Indeed, only cytophilic IgGs are potent and, in agreement with immunoepidemiological findings, IgG3 is superior to IgG1. Very low Ab concentrations (>700 pM), i.e., in the range of molecules having a hormonal effect, are effective, in contrast to Abs having a direct, neutralizing effect. Finally, Ab-dependent cell-mediated inhibition proved to require the synergistic activation of both FcgammaRIIa and FcgammaRIIIa which both distinguish it from other Ab-dependent cellular cytotoxicity and implies that all MN are not equally effective. These findings have both fundamental and practical implications, particularly for vaccine discovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312157     DOI: 10.4049/jimmunol.178.5.3099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

2.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

3.  Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.

Authors:  Christian Roussilhon; Philippe Brasseur; Patrice Agnamey; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

4.  Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.

Authors:  Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

5.  Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Authors:  Amanda Maestre; Carlos Muskus; Victoria Duque; Olga Agudelo; Pu Liu; Akihide Takagi; Francis B Ntumngia; John H Adams; Kim Lee Sim; Stephen L Hoffman; Giampietro Corradin; Ivan D Velez; Ruobing Wang
Journal:  PLoS One       Date:  2010-07-15       Impact factor: 3.240

6.  A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria.

Authors:  Pattamawan Chimma; Christian Roussilhon; Panudda Sratongno; Ronnatrai Ruangveerayuth; Kovit Pattanapanyasat; Jean-Louis Pérignon; David J Roberts; Pierre Druilhe
Journal:  PLoS Pathog       Date:  2009-10-23       Impact factor: 6.823

7.  Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya.

Authors:  Indu Malhotra; Arlene Dent; Peter Mungai; Alex Wamachi; John H Ouma; David L Narum; Eric Muchiri; Daniel J Tisch; Christopher L King
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

8.  Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.

Authors:  John P A Lusingu; Samwel Gesase; Salum Msham; Filbert Francis; Martha Lemnge; Misago Seth; Samwel Sembuche; Acleus Rutta; Daniel Minja; Method D Segeja; Samuel Bosomprah; Simon Cousens; Ramadhani Noor; Roma Chilengi; Pierre Druilhe
Journal:  Malar J       Date:  2009-07-17       Impact factor: 2.979

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

10.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.